Please login to the form below

Not currently logged in
Email:
Password:

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

EMA clears Novo Nordisk’s long-acting haemophilia A drug

EMA clears Novo Nordisk’s long-acting haemophilia A drug

Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and

Latest news

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders.  During 2016 Eloctate and Alprolix

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics